Table 3.
Correlations of clinical features of HCC patients with circulating Tregs and Bregs.
| DESS evaluated | Tregs | Bregs | ||
|---|---|---|---|---|
| Clinicopathological Characteristic | r | P | r | P |
| Weight Loss | -0.339 | 0.043* | - | - |
| HBV Infection History | 0.360 | 0.031* | - | - |
| Leucocyte | 0.363 | 0.029* | - | - |
| Hepatitis B e Antigen | - | - | 0.527 | 0.030* |
| HBV DNA Copy number | - | - | 0.532 | 0.028* |
| Ferritin | -0.451 | 0.006** | - | - |
| Numbers of up-regulated tumor markers # | -0.376 | 0.024* | - | - |
| Portal vein tumor thrombosis | -.408* | 0.014* | - | - |
| Hepatic vein invasion | -.413* | 0.012* | - | - |
| BCLC score | -0.443 | 0.007** | - | - |
| TNM stage(AJCC) | -0.347 | 0.038* | - | - |
(*, ** stands for P < 0.05, 0.01, respectively)
# Tested tumor markers:α-fetoprotein; cancer antigen 125; cancer antigen 153; cancer antigen 199; Ferritin; Carcino-embryonic antigen; prostate specific antigen.
HCC: Hepatocellular carcinoma; Tregs: Regulatory T cells; Bregs: Regulatory B cells; HBV: Hepatitis B virus; BCLC: Barcelona Clinic Liver Cancer Staging System; TNM (AJCC): Tumor-Node-Metastasis Staging System (American Joint Committee on Cancer).